


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-9.2US

In Re Application Of: ARORA et al.



Serial No.
10/611,386

Filing Date
July 1, 2003

Examiner
TBA

Group Art Unit
TBA

Title: DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR


☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-9.2US

In Re Application: ARORA et al.



Serial No.

10/611,386

Filing Date

July 1, 2003

Examiner

TBA

Group Art Unit

TBA

DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on December 23, 2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Signature of Person Mailing Correspondence

Elise Ariel

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

Signature

Dated: December 23, 2003

Jayadeep R. Deshmukh, Esq.

Reg. No. 34,507

Ranbaxy Pharmaceuticals Inc.

600 College Road East, Suite 2100

Princeton, NJ 08540

Tel.: (609) 720-5608

Fax.: (609) 514-9779

CC:

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-9.2US	Serial No.: 10/611,386
	Applicants: ARORA <i>et al.</i>	
	Filed: 7/1/2003	Group: TBA

C5	BINKLEY, "Synthesis of Methyl 2,6-Dideoxy-3-C-Mathyl- α -D-Ribo-Hexopyranoside (Methyl α -D-Mycaroside), A Component of the Antitumor Agent Mithramycin," <i>J. Carbohydr. Chem.</i> , 4:227 (1985)
C6	BOUVENG, "Phenylisocyanate Derivatives of Carbohydrates," <i>Acta. Chem. Scand.</i> , 15:96-100 (1961)
C7	CHISOLM et al, "Monoclonal antibodies to the integrin α -4 subunit inhibit the murine contact hypersensitivity response," <i>Eur. J. Immunol.</i> , 23:682 (1993)
C8	FERGUSON et al, "Two integrin-binding peptides abrogate T cell-mediated immune responses <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci (USA)</i> , 88:8072 (1991)
C9	HASEGAWA et al, "Synthesis of N-[2-S-(2-Acetamido-2,3-Dideoxy-D-Glucopyranose-3-yl)-2-Thio-D-Lactoyl]-L-Alanyl-D-Isoglutamine, <i>J. Carbohydr. Chem.</i> , 3:331-341 (1984)
C10	KING and ALLBUTT, "Stereochemistry of bimolecular nucleophilic opening of a dioxolenium ring fused to an anchored cyclohexane system," <i>Can. J. Chem.</i> , 47:1455 (1969)
C11	KING and ALLBUTT, "Remarkable stereoselectivity in the hydrolysis of dioxolenium ions and orthoesters fused to anchored six-membered rings," <i>Can. J. Chem.</i> , 48:1754 (1970)
C12	KOMORIYA et al, "The Minimal Essence Sequence for a Major Cell Type-specific Adhesion Site (CS1) within the Alternatively Spliced Type III Connecting Segment Domain of Fibronectin Is Leucine-Aspartic Acid-Valine," <i>J. Biol. Chem.</i> , 266:15075 (1991)
C13	MANI et al, "Heparan/Chondroitin/Dermatan Sulfate Primer 2-(6-Hydroxynaphthyl)-O- β -D-Xylopyranoside Preferentially Inhibits Growth of Transformed Cells," <i>Cancer Res.</i> , 58, pp. 1099-1104 (1998)
C14	"Monosaccharides," <i>Methods in Carbohydr. Chem.</i> , 1:107 (1962) & 1:191 (1962)
C15	NOWLIN et al, "A Novel Cyclic Pentapeptide Inhibits α 4 β 1 and α 5 β 1 Integrin-mediated Cell Adhesion," <i>J. Biol. Chem.</i> , 268(27):20352 (1993)
C16	PODOLSKY et al, "Attenuation of Colitis in the Cotton-top Tamarin by Anti- α 4 integrin Monoclonal Antibody," <i>J. Clin. Invest.</i> , 92: 372 (1993)
C17	WAHL et al, "Synthetic Fibronectin Peptides Suppress Arthritis in Rats by Interrupting Leukocyte Adhesion and Recruitment," <i>J. Clin. Invest.</i> , 94:655 (1994)
C18	YANG et al, "Inhibition of insulinitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors," <i>Proc. Natl. Acad. Sci. (USA)</i> , 90:10494 (1993)
C19	YEDNOCK et al, "Prevention of experimental autoimmune encephalomyelitis by antibodies against α 4 β 1 integrin," <i>Nature (Lond)</i> , 356:63 (1992)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-9.2US

Serial No.: 10/611,386

Applicants: ARORA *et al.*

Filed: 7/1/2003

Group: TBA

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	2,715,121	8/9/1955	Glen <i>et al.</i>			
	A2	4,056,322	11/1/1977	Gordon <i>et al.</i>	536	4	
	A3	4,735,934	4/5/1988	Gordon	514	25	
	A4	4,996,195	2/26/1991	Ronsen <i>et al.</i>	514	23	
	A5	5,010,058	4/23/1991	Ronsen <i>et al.</i>	514	23	
	A6	5,637,570	6/10/1997	Arora <i>et al.</i>	514	25	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	B1	EP 379397 ✓	7/25/1990	EPO	C07H	9/04		
	B2	EP 404136 ✓	12/27/1990	EPO	C07H	15/12		
	B3	WO 91/04862 ✓	4/18/1991	PCT	B41J	2/175		
	B4	WO 92/00995 ✓	1/23/1992	PCT	C07K	7/00		
	B5	WO 94/11381 ✓	5/26/1994	PCT	C07H	15/12		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	ABRAHAM <i>et al.</i> , " α_4 Integrins Mediate Antigen-induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep," <i>J. Clin. Invest.</i> , 93:776 (1994) ✓
	C2	ASPINALL <i>et al.</i> , "The hex-5-enose degradation: zinc dust cleavage of 6-deoxy-6-iodo- α -D-galactopyranosidic linkages in methylated di- and trisaccharides," <i>Can. J. Chem.</i> , 62:2728-2735 (1984) ✓
	C3	BARON <i>et al.</i> , "Surface Expression of α_4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma," <i>J. Exp. Med.</i> , 177:57 (1993) ✓
	C4	BHATTACHARJEE and GORIN, "Hydrogenolysis of carbohydrate acetals, ketals, and cyclic orthoesters with lithium aluminium hydride-aluminium trichloride," <i>Can. J. Chem.</i> , 47:1195 (1969) ✓

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.